Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full ...

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial ...

Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

CRISPR Therapeutics (CRSP) stock falls as company's Q2 results miss consensus amid focus on its Cagevy gene therapy developed with Vertex Pharma (VRTX). Read more here.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here’s what to ...

Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, ...

Shares of Vertex Pharmaceuticals plunged more than 14% to $404.89 after it release disappointing top-line results from its recently completed Phase II, randomized, double-blind, placebo-controlled ...

U.S. stock futures are pointing higher after indexes surged Monday to rebound from last week's selloff. Nasdaq futures are 0.4% higher after the tech-heavy index gained 2% in the prior session, while ...

Key Takeaways The S&P 500 declined 0.5% on Tuesday, Aug. 5, 2025, as a key gauge of the services sector showed a slump in July and trade talks remained in focus.Gartner shares tumbled after the IT ...